Literature DB >> 8197647

The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.

B J Lin1, K K Chen, M T Chen, L S Chang.   

Abstract

OBJECTIVE: To understand the time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.
METHODS: A total of 20 consecutive patients with adenocarcinoma of the prostate with bony metastasis were enrolled in this study. Their mean age was 72.8 years old (range, 57 to 82 years). Pretreatment serum testosterone levels were obtained in all men. Thirteen men were treated with bilateral orchiectomy. Immediately after removal of testes, serial blood samplings for serum testosterone levels were drawn every fifteen minutes for the first two hours, then hourly for another sixteen hours. Seven men were treated with oral estrogen diethylstilbestrol (DES), 3 mg per day. Serum testosterone levels were checked on a weekly basis for two months, and then biweekly for another two months.
RESULTS: Castration time of bilateral orchiectomy ranges from three to twelve hours (mean, 8.6 hours). The biological half-life of serum testosterone was from thirty to sixty minutes (mean, 45 minutes). Castration time of oral estrogen (DES) was from twenty-one to sixty days (mean, 38.3 days).
CONCLUSIONS: Bilateral orchiectomy and oral estrogen were both effective ways of castration for patients with bony metastatic prostatic cancer. Bilateral orchiectomy provides a more rapid castration and is one hundred seven times faster than oral estrogen in reaching castrate level.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8197647     DOI: 10.1016/0090-4295(94)90145-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.

Authors:  Timothy N Clinton; Solomon L Woldu; Ganesh V Raj
Journal:  Expert Opin Pharmacother       Date:  2017-05-19       Impact factor: 3.889

Review 2.  Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.

Authors:  Bobby Shayegan; Frédéric Pouliot; Alan So; John Fernandes; Joseph Macri
Journal:  Can Urol Assoc J       Date:  2017-06       Impact factor: 1.862

Review 3.  [Androgen deprivation for advanced prostate cancer].

Authors:  A Heidenreich; D Pfister; C H Ohlmann; U H Engelmann
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

4.  Effective testosterone suppression for prostate cancer: is there a best castration therapy?

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2009

Review 5.  Challenges of managing elderly men with prostate cancer.

Authors:  Gautam G Jha; Vidhu Anand; Ayman Soubra; Badrinath R Konety
Journal:  Nat Rev Clin Oncol       Date:  2014-05-13       Impact factor: 66.675

6.  HERO trial: A rescue from injectable androgen deprivation therapy.

Authors:  Satish Kumar Ranjan
Journal:  Indian J Urol       Date:  2021-04-01

7.  Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer.

Authors:  Rohan Garje; Adithya Chennamadhavuni; Sarah L Mott; Isaac Matthew Chambers; Paul Gellhaus; Yousef Zakharia; James A Brown
Journal:  Clin Genitourin Cancer       Date:  2019-09-26       Impact factor: 2.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.